We feel now is a pretty good time to analyse HLS Therapeutics Inc.'s (TSE:HLS) business as it appears the company may be on the cusp of a considerable accomplishment. HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s loss has recently broadened since it announced a US$24m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$26m, moving it further away from breakeven. As path to profitability is the topic on HLS Therapeutics' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

View our latest analysis for HLS Therapeutics

Consensus from 4 of the Canadian Pharmaceuticals analysts is that HLS Therapeutics is on the verge of breakeven. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$14m in 2025. Therefore, the company is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 69% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected. earnings-per-share-growth

We're not going to go through company-specific developments for HLS Therapeutics given that this is a high-level summary, though, take into account that by and large a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

One thing we would like to bring into light with HLS Therapeutics is its relatively high level of debt. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in HLS Therapeutics' case is 84%. Note that a higher debt obligation increases the risk around investing in the loss-making company.



Next Steps:

There are too many aspects of HLS Therapeutics to cover in one brief article, but the key fundamentals for the company can all be found in one place – HLS Therapeutics' company page on Simply Wall St. We've also put together a list of essential factors you should look at:

Valuation: What is HLS Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether HLS Therapeutics is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on HLS Therapeutics’s board and the CEO’s background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.